Novavax (NVAX) Net Cash Flow (2010 - 2026)
Novavax (NVAX) posted quarterly Net Cash Flow of -$23.1 million for Q1 2026, up 91.32% year-over-year from -$12.1 million in Q1 2025, and up 9.81% quarter-over-quarter from -$25.6 million in Q4 2025.
Novavax (NVAX) Net Cash Flow (2010 - 2026) Analysis & Trends
Novavax's Net Cash Flow history runs 17 years deep, the most recent figure standing at -$23.1 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 91.32% year-over-year to -$23.1 million; the TTM figure through Mar 2026 stood at -$52.4 million (up 75.26% YoY), while the FY2025 annual figure was -$295.2 million, down 860.89% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$23.1 million, up from -$25.6 million in the prior quarter.
- The five-year high for Net Cash Flow was $199.8 million in Q2 2024, with the low at -$703.5 million in Q1 2023.
- The 5-year median for Net Cash Flow is -$32.6 million (2024), against an average of -$76.5 million.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow slumped 1390.19% in 2023, then soared 268.76% in 2024.
- Novavax's Net Cash Flow stood at $51.6 million in 2022, then plunged by 265.77% to -$85.5 million in 2023, then jumped by 61.88% to -$32.6 million in 2024, then advanced by 21.43% to -$25.6 million in 2025, then climbed by 9.81% to -$23.1 million in 2026.
- Business Quant data shows NVAX's Net Cash Flow at -$23.1 million in Q1 2026, -$25.6 million in Q4 2025, and $13.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | -36.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.71 Mn |
| Jun 30, 2026 | -36.71 Mn |
| Mar 31, 2026 | -23.09 Mn |
| Mar 31, 2026 | -23.09 Mn |
| Dec 31, 2025 | -25.60 Mn |
| Dec 31, 2025 | -25.60 Mn |
| Sep 30, 2025 | 13.75 Mn |
| Sep 30, 2025 | 13.75 Mn |
| Jun 30, 2025 | -17.44 Mn |
| Jun 30, 2025 | -17.44 Mn |
| Mar 31, 2025 | -265.88 Mn |
| Mar 31, 2025 | -265.88 Mn |
| Dec 31, 2024 | -32.58 Mn |
| Dec 31, 2024 | -32.58 Mn |
| Sep 30, 2024 | -113.00 Mn |
| Sep 30, 2024 | -113.00 Mn |
| Jun 30, 2024 | 199.78 Mn |
| Jun 30, 2024 | 199.78 Mn |
| Mar 31, 2024 | -84.92 Mn |
| Mar 31, 2024 | -84.92 Mn |